Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting

Author： Navari Rudolph M  

Publisher： Informa Healthcare

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.16, Iss.12, 2007-12, pp. : 1977-1985

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting

By Van Belle Simon JP   Cocquyt Veronique  

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 18, 2008-12 ,pp. : 3261-3270

Informa Healthcare

Access to resources Recommend Favorite

Tachykinin NK1 receptor antagonists for the control of chemotherapy-induced nausea and vomiting

By Gale Jeremy D   O’Neill Brian T   Humphrey John M  

Expert Opinion on Therapeutic Patents, Vol. 11, Iss. 12, 2001-12 ,pp. : 1837-1847

Informa Healthcare

Access to resources Recommend Favorite

Review of palonosetron: emerging data distinguishing it as a novel 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting

By Saito Mitsue   Tsukuda Mamoru  

Expert Opinion on Pharmacotherapy, Vol. 11, Iss. 6, 2010-04 ,pp. : 1003-1014

Informa Healthcare

Access to resources Recommend Favorite

5-HT Receptor Antagonists for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Comparison of Their Pharmacology and Clinical Efficacy

By Gregory R.E.   Ettinger D.S.  

Drugs, Vol. 55, Iss. 2, 1998-02 ,pp. : 173-189

Adis International

Access to resources Recommend Favorite

Risk–benefit of antiemetics in prevention and treatment of chemotherapy-induced nausea and vomiting

By Herrstedt Jørn  

Expert Opinion on Drug Safety, Vol. 3, Iss. 3, 2004-05 ,pp. : 231-248

Informa Healthcare

Access to resources Recommend Favorite